CONMED
CNMD
280 hedge funds and large institutions have $2.45B invested in CONMED in 2024 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 97 increasing their positions, 98 reducing their positions, and 44 closing their positions.
731% more call options, than puts
Call options by funds: $8.3M | Put options by funds: $999K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
5.83% more ownership
Funds ownership: 110.07% → 115.9% (+5.8%)
0% more capital invested
Capital invested by funds: $2.44B → $2.45B (+$9.67M)
1% less repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 98
9% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 44
3% less funds holding
Funds holding: 290 → 280 (-10)
Top Buyers
| 1 |
SAM
Silvercrest Asset Management
New York
|
+$69.7M |
| 2 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$60.1M |
| 3 |
Neuberger Berman Group
New York
|
+$21.8M |
| 4 |
Fisher Asset Management
Camas,
Washington
|
+$8.51M |
| 5 |
N
Natixis
Paris,
France
|
+$7.27M |
Top Sellers
| 1 |
JP Morgan Chase
New York
|
-$11.2M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$8.61M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$6.86M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$6.65M |
| 5 |
Renaissance Technologies
New York
|
-$5.51M |
CNMD Hedge Fund Activity: Q4 2024 in Review
280 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in CONMED (CNMD) for Q4 2024, worth a combined $2.45B — up 0.4% from $2.44B a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of CNMD and 40 opened new positions — a net loss of 4 holders — while 98 trimmed existing stakes and 97 added.
The largest buyer was Silvercrest Asset Management, opening a new position worth an estimated $69.7M. The largest seller was JP Morgan Chase, cutting an estimated $11.2M.
- 280 institutional investors held CONMED (CNMD) as of Q4 2024, down from 290 in Q3 2024.
- Funds reported $2.45B of CONMED stock for Q4 2024, up 0.4% quarter-over-quarter.
- 40 funds opened new CONMED positions in Q4 2024 and 44 closed out, a net change of -4 holders.
- The largest CONMED buyer in Q4 2024 was Silvercrest Asset Management, an estimated $69.7M added.
- The largest CONMED seller in Q4 2024 was JP Morgan Chase, an estimated $11.2M sold.
Based on aggregated 13F filings for Q4 2024.